The biology of the combretastatins as tumour vascular targeting agents

International Journal of Experimental Pathology

Volumn 83, Issue 1, 2002, Pages 21-38

  Tozer, Gillian M ^a,b   Kanthou, Chryso ^a   Parkins, Charles S ^a   Hill, Sally A ^a  

^a Gray Cancer Institute   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Blood flow; Cancer therapy; Combretastatins; Tubulin cytoskeleton; Tumour vascular targeting

Indexed keywords

COLCHICINE DERIVATIVE; COMBRETASTATIN; COMBRETASTATIN A1; COMBRETASTATIN A4; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD FLOW VELOCITY; BLOOD VESSEL; CANCER; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; TISSUE BLOOD FLOW; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES;

EID: 0036282385     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2613.2002.00211.x     Document Type: Review

References (120)

1. Antimitotic activity of diaryl compounds with structures resembling combretastatin A-4
2. Vascular reactions of normal and malignant tissues in vivo. VI. The role of hypotension in the action of components of podophyllotoxin on transplanted sarcomas
3. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
4. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
5. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
6. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: Relation to vascular effects
7. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability
8. 4 prodruginduced disruption of tumour perfusion and energetic status
9. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
10. Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy
11. Anti-tumour activity of flavone acetic acid (NSC 347512) in mice - Influence of immune status
12. Rho GTPases and their effector proteins
13. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model
14. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
15. Combretastatin A-4 prodrug: A potent inhibitor of malignant hemangioendothelioma cell proliferation
16. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy
17. Studies in tissue metabolism. IX. The action of colchicine and B. typhosus extract
18. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy
19. Tumour vasculature as a target for cancer therapy
20. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
21. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents
22. Antitumor responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice
23. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
24. ZD6126: A new agent causing selective damage of tumor vasculature
25. Endothelial cell proliferation as a novel approach to targeting tumour therapy
26. Vascular occlusion and tumour cell death
27. Endothelial cell proliferation in experimental tumours
28. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor
29. Identification and characerization of the blood vessels of solid tumors that are leaky to circulating macromolecules
30. Tumour vasculature as a target for anticancer therapy
31. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
32. Isolation limb perfusion with tumour necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas
33. 4An rat glioma
34. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub)
35. Angiogenesis and angiogenesis inhibition: An overview
36. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
37. Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man
38. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
39. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
40. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
41. Microtubules and signal transduction
42. Novel B-ring modified combretastatin analogues: Syntheses and antineoplastic activity
43. Vinca alkaloids: Anti-vascular effects in a murine tumour
44. Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid
45. Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour action
46. Activity of combretastatin A1 phosphate in murine models of liver metastasis
47. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700
48. Stoppage of blood flow in 3-methylcholanthrene-induced primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect
49. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
50. Combretastatins: Novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy
51. Tumor infarction in mice by antibodydirected targeting of tissue factor to tumor vasculature
52. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
53. In vivo targets of recombinant human tumour necrosis factor-α: Blood flow, oxygen consumption and growth of isotransplanted rat tumours
54. The tumour vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
55. Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
56. Occlusion of the hepatic artery in man
57. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
58. Myosin light chain kinase: An actin-binding protein that regulates an ATP-dependent interaction with myosin
59. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy
60. Nitric oxide production by tumour tissue: Impact on the response to photodynamic therapy
61. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment
62. Antimitotic and cell growth inhibitory properties of combretastatin A-4-1ike ethers
63. Clinical applications of TNF-alpha in cancer
64. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown
65. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
66. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin
67. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structural-activity study
68. Microtubule depolymerization induces stress fibers, focal adhesions, and DNA synthesis via the GTP-binding protein Rho
69. Red blood cell behavior at low flow rate in microvessels
70. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer
71. Factors determining the action of colchicine on tumour growth
72. Role of tumor necrosis factor in flavone acetic acid induced vascular shutdown
73. Tumor vascular targeting using a tumor-tissue endothelium-specific monoclonal antibody as an effective strategy for cancer chemotherapy
74. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI
75. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile
76. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines
77. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues
78. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors
79. Vascular markers for murine tumours
80. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines
81. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma
82. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
83. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy
84. Angiostatin induces and sustains dormancy of human primary tumors in mice
85. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
86. Novel combretastatin analogues effective against murine solid tumors: Design and structure-activity relationships
87. TZT-1027, an antimicrotubule agent attacks tumor vasculature and induces tumor cell death
88. Modifications of endothelial tubulin by nitric oxide (NO): Response to microtubule-depolymerising agent, combretastatin A-4-P (CA-4-P)
89. Ischemia reperfusion injury in tumors: The role of oxygen radicals and nitric oxide
90. Involvement of oxygen free radicals in ischaemia-reperfusion injury to murine tumours: Role of nitric oxide
91. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide
92. Organ targeting in vivo using phage display peptide libraries
93. Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow-modifying agents
94. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate
95. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent
96. Antineoplastic agents, 122. Constituents of Combretum caffrum
97. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs
98. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4
99. Isolation, structure, and synthesis of combretastatins A-1 and B-l, potent new inhibitors of microtubule assembly derived from Combretum caffrum
100. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs
101. Antineoplastic agents. 379. Synthesis of phenstatin phosphate
102. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
103. Dynamic gadolinium-enhanced MRI of tumors: Effects of CA4P on tumor blood flow
104. Phase I study of weekly intravenous combretastatin A4 phosphate (CA4P): Pharmacokinetics and toxicity
105. Effect of colchicine on human carcinoma
106. Genes expressed in human tumor endothelium
107. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum
108. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma
109. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine
110. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability
111. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
112. Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation
113. Oxygenation of mammary tumors: From isotransplanted rodent tumors to primary malignancies in patients
114. Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density
115. Effects of novel and conventional anti-cancer agents on human endothelial permeability: Influence of tumoursecreted factors
116. The interaction with tubulin of a series of stilbenes based on combretastatin A-4
117. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody
118. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid